Laos vs Moldova: Average cost of drugs for extensively drug-resistant tuberculosis
Laos
1,250 constant 2022 US$
in 2024
Moldova
1,400 constant 2022 US$
in 2024
Laos rank
37th
Moldova rank
36th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Laos
- Moldova
How they compare
Moldova currently reports 1,400 constant 2022 US$ against 1,250 constant 2022 US$ in Laos, a difference of 150 constant 2022 US$.
That makes Moldova's figure about 1.1 times Laos's.
Across all 7 years both countries report, Moldova has been ahead every year.
Laos ranks 37th and Moldova ranks 36th of 56 countries.
Moldova has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Laos | Moldova | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,250 constant 2022 US$ | 5,169 constant 2022 US$ | 3,919 constant 2022 US$ | Moldova |
| 2020s | 1,240 constant 2022 US$ | 2,970 constant 2022 US$ | 1,730 constant 2022 US$ | Moldova |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Laos or Moldova?
- Moldova, at 1,400 constant 2022 US$ against 1,250 constant 2022 US$ in Laos as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Laos and Moldova?
- 150 constant 2022 US$, with Moldova ahead.
- How many years of comparable data are there for Laos and Moldova?
- 7 years are reported by both, from 2018 to 2024.
- How do Laos and Moldova rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Laos ranks 37th and Moldova ranks 36th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.